Weight loss gummies claim to burn fat, suppress hunger, and boost your metabolism to help with weight loss, but these ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

US biotech Rhythm Pharmaceuticals (Nasdaq: RYTM) has reacquired the rights to its obesity treatment Imcivree (setmelanotide) ...

- Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission - - Strengthened ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

Rhythm’s lead asset, IMCIVREE ® (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the U.S. Food and Drug Administration (FDA) to reduce excess body ...